Genmab A/S Sponsored ADR $GMAB Position Lessened by Signaturefd LLC

Signaturefd LLC reduced its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 13.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,124 shares of the company’s stock after selling 1,400 shares during the period. Signaturefd LLC’s holdings in Genmab A/S were worth $188,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Headlands Technologies LLC raised its holdings in Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after buying an additional 1,464 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after buying an additional 1,070 shares in the last quarter. Parallel Advisors LLC grew its position in shares of Genmab A/S by 377.5% in the second quarter. Parallel Advisors LLC now owns 3,720 shares of the company’s stock valued at $77,000 after purchasing an additional 2,941 shares during the last quarter. Brooklyn Investment Group grew its position in shares of Genmab A/S by 729.3% in the first quarter. Brooklyn Investment Group now owns 4,246 shares of the company’s stock valued at $83,000 after purchasing an additional 3,734 shares during the last quarter. Finally, Advisors Preferred LLC acquired a new stake in shares of Genmab A/S in the first quarter valued at about $84,000. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

GMAB has been the topic of several research analyst reports. Truist Financial raised their price target on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, July 8th. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target on the stock in a research report on Tuesday, September 23rd. HC Wainwright raised their price target on Genmab A/S from $36.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday. Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Finally, Wall Street Zen raised Genmab A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 26th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $40.80.

Genmab A/S Trading Up 1.1%

NASDAQ GMAB opened at $32.12 on Friday. The stock’s 50 day moving average is $25.64 and its two-hundred day moving average is $22.33. The company has a market capitalization of $20.61 billion, a price-to-earnings ratio of 16.14, a PEG ratio of 1.80 and a beta of 0.98. Genmab A/S Sponsored ADR has a 1-year low of $17.24 and a 1-year high of $32.24.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. The company had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. On average, analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.